The Maricann Group Inc. recently announced that they received their encapsulated cannabis oil license from Health Canada as of late November 2017. First founded in 2013, the Maricann Group is a Canadian-based, publicly-traded medical cannabis company that serves thousands of patients across Canada.
The company is actively in control of their entire process from the cultivation of plants, extraction, research and development processing, to the marketing and sales of cannabis to their consumers.
Paired with a unique patented technology, the Maricann Group’s cannabis oil capsules will aim to provide patients with another option of immediate and consistent cannabinoid therapy.
The Maricann Group’s Pathway to Pills
Since receiving their license to encapsulate as of Nov 17, 2017, the company has commenced the production of encapsulated cannabis oil. Intended for individual medical use, the Maricann Capsules provide an important variation of medicine as well as several other benefits for its users.
As opposed to other methods of consuming cannabis (i.e. smoking, vaping, and eating), cannabis oil capsules in general provide the same immediate effects to the consumer without the difficulty or resistance that can come with the previous methods. The capsules become a part of daily life and is a treatment option delivered in a format that most patients find more comfortable and compelling. For physicians, an encapsulated pill gives them more control over the dosage and they can then work with the patient to choose the right cannabinoid therapy for them.
The Maricann Group’s pills however work with a patented technology called Vesisorb™ that make their cannabis oil capsules not only different from the others, but possibly even better. Firstly, the all-natural cannabis extract is delivered in a vegan capsule format and four types will be available to start; 15mg and 25mg of cannabidiol (CBD), or 5mg and 10mg of THC.
A common and existing issue with cannabis oil capsules are that the cannabinoids are almost insoluble in water. Most hardly make it into the system by the time they are digested, or more often, metabolized. Maricann Group’s Vesisorb™ technology however allows the oil to disperse more evenly in a water-environment like the stomach, providing higher and more immediate blood levels of active cannabinoids. This not only makes it more consistent for the consumer, but also more potent as the technology does not allow the cannabinoids to be destroyed by the liver, but instead is absorbed quickly into the stomach lining.
The company’s CEO Benjamin Ward says, “Maricann is focused on expanding capacity in a truly differentiated product offering, in support of its previously announced joint pharmacy initiative and future global export opportunities.”
Maricann Group Inc expects patients to be able to order their cannabis oil capsules starting in early 2018.
